AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-77
Results: 26-50/77
EFFICACY AND TOLERABILITY OF CANCER NEUROIMMUNOTHERAPY WITH SUBCUTANEOUS LOW-DOSE INTERLEUKIN-2 AND THE PINEAL HORMONE MELATONIN - A PROGRESS REPORT OF 200 PATIENTS WITH ADVANCED SOLID NEOPLASMS
Authors: LISSONI P ARDIZZOIA A BARNI S BRIVIO F TISI E ROVELLI F TANCINI G MAESTRONI G FUMAGALLI L
Citation: P. Lissoni et al., EFFICACY AND TOLERABILITY OF CANCER NEUROIMMUNOTHERAPY WITH SUBCUTANEOUS LOW-DOSE INTERLEUKIN-2 AND THE PINEAL HORMONE MELATONIN - A PROGRESS REPORT OF 200 PATIENTS WITH ADVANCED SOLID NEOPLASMS, Oncology Reports, 2(6), 1995, pp. 1063-1068
A RANDOMIZED STUDY OF TAMOXIFEN ALONE VERSUS TAMOXIFEN PLUS MELATONININ ESTROGEN RECEPTOR-NEGATIVE HEAVILY PRETREATED METASTATIC BREAST-CANCER PATIENTS
Authors: LISSONI P ARDIZZOIA A BARNI S PAOLOROSSI F TANCINI G MEREGALLI S ESPOSTI D ZUBELEWICZ B BRACZOWSKI R
Citation: P. Lissoni et al., A RANDOMIZED STUDY OF TAMOXIFEN ALONE VERSUS TAMOXIFEN PLUS MELATONININ ESTROGEN RECEPTOR-NEGATIVE HEAVILY PRETREATED METASTATIC BREAST-CANCER PATIENTS, Oncology Reports, 2(5), 1995, pp. 871-873
TREATMENT OF INTERFERON-ALPHA 2A(IFN)-INDUCED THROMBOCYTOPENIA BY THEPINEAL NEUROHORMONE MELATONIN (MTL)
Authors: LISSONI P BARNI S TANCINI G ADIZZOIA A PAOLOROSSI F
Citation: P. Lissoni et al., TREATMENT OF INTERFERON-ALPHA 2A(IFN)-INDUCED THROMBOCYTOPENIA BY THEPINEAL NEUROHORMONE MELATONIN (MTL), European journal of cancer, 31A, 1995, pp. 583-583
PRESERVATION OF THE ORGAN IN THE THERAPY OF INFILTRATING BLADDER-TUMORS
Authors: ROCCO F SCANDINO E CARMIGNANI L DECOBELLI O ANDRES M CRISPINO S TANCINI G PAOLOROSSI F BOYLE P MAISONNEUVE P
Citation: F. Rocco et al., PRESERVATION OF THE ORGAN IN THE THERAPY OF INFILTRATING BLADDER-TUMORS, European journal of cancer, 31A, 1995, pp. 1154-1154
A RANDOMIZED STUDY OF NEUROIMMUNOTHERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN COMPARED TO SUPPORTIVE CARE ALONE IN PATIENTS WITH UNTREATABLE METASTATIC SOLID TUMOR
Authors: LISSONI P BARNI S FOSSATI V ARDIZZOIA A CAZZANIGA M TANCINI G FRIGERIO F
Citation: P. Lissoni et al., A RANDOMIZED STUDY OF NEUROIMMUNOTHERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN COMPARED TO SUPPORTIVE CARE ALONE IN PATIENTS WITH UNTREATABLE METASTATIC SOLID TUMOR, Supportive care in cancer, 3(3), 1995, pp. 194-197
INTRACAVITARY THERAPY OF NEOPLASTIC EFFUSIONS WITH CYTOKINES - COMPARISON AMONG INTERFERON-ALPHA, INTERFERON-BETA AND INTERLEUKIN-2
Authors: LISSONI P BARNI S TANCINI G ARDIZZOIA A TISI E ANGELI M RIZZI A
Citation: P. Lissoni et al., INTRACAVITARY THERAPY OF NEOPLASTIC EFFUSIONS WITH CYTOKINES - COMPARISON AMONG INTERFERON-ALPHA, INTERFERON-BETA AND INTERLEUKIN-2, Supportive care in cancer, 3(1), 1995, pp. 78-80
RELATION BETWEEN MACROPHAGE AND T-HELPER-2 LYMPHOCYTE FUNCTIONS IN HUMAN NEOPLASMS - NEOPTERIN, INTERLEUKIN-10 AND INTERLEUKIN-6 BLOOD-LEVELS IN EARLY OR ADVANCED SOLID TURNERS
Authors: LISSONI P ROVELLI F TISI E BRIVIO F ARDIZZOIA A BARNI S TANCINI G SAUDELLI M CESANA E VIGANO MG
Citation: P. Lissoni et al., RELATION BETWEEN MACROPHAGE AND T-HELPER-2 LYMPHOCYTE FUNCTIONS IN HUMAN NEOPLASMS - NEOPTERIN, INTERLEUKIN-10 AND INTERLEUKIN-6 BLOOD-LEVELS IN EARLY OR ADVANCED SOLID TURNERS, Journal of biological regulators and homeostatic agents, 9(4), 1995, pp. 146-149
NEUROIMMUNOTHERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN IN AIDS PATIENTS WITH CD4 CELL NUMBER BELOW 200 MM(3) - A BIOLOGICAL PHASE-II STUDY/
Authors: LISSONI P VIGORE L RESCALDANI R ROVELLI F BRIVIO F GIANI L BARNI S TANCINI G ARDIZZOIA A VIGANO MG
Citation: P. Lissoni et al., NEUROIMMUNOTHERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN IN AIDS PATIENTS WITH CD4 CELL NUMBER BELOW 200 MM(3) - A BIOLOGICAL PHASE-II STUDY/, Journal of biological regulators and homeostatic agents, 9(4), 1995, pp. 155-158
TREATMENT OF CANCER-RELATED THROMBOCYTOPENIA BY LOW-DOSE SUBCUTANEOUSINTERLEUKIN-2 PLUS THE PINEAL HORMONE MELATONIN - A BIOLOGICAL PHASE-II STUDY
Authors: LISSONI P BARNI S BRIVIO F ROSSINI F FUMAGALLI L TANCINI G
Citation: P. Lissoni et al., TREATMENT OF CANCER-RELATED THROMBOCYTOPENIA BY LOW-DOSE SUBCUTANEOUSINTERLEUKIN-2 PLUS THE PINEAL HORMONE MELATONIN - A BIOLOGICAL PHASE-II STUDY, Journal of biological regulators and homeostatic agents, 9(2), 1995, pp. 52-54
CORRELATION BETWEEN PRETREATMENT SERUM LEVELS OF NEOPTERIN AND RESPONSE TO INTERLEUKIN-2 IMMUNOTHERAPY IN CANCER-PATIENTS
Authors: LISSONI P BARNI S ARDIZZOIA A SCARDINO E TANCINI G VIGANO MG
Citation: P. Lissoni et al., CORRELATION BETWEEN PRETREATMENT SERUM LEVELS OF NEOPTERIN AND RESPONSE TO INTERLEUKIN-2 IMMUNOTHERAPY IN CANCER-PATIENTS, Journal of biological regulators and homeostatic agents, 9(1), 1995, pp. 21-23
ENDOCRINE EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN CANCER-PATIENTS
Authors: ROVELLI F BARNI S TANCINI G ARDIZZOIA A LISSONI P
Citation: F. Rovelli et al., ENDOCRINE EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN CANCER-PATIENTS, Tumori, 81(6), 1995, pp. 438-439
CLINICAL EFFICACY OF CANCER SUBCUTANEOUS IMMUNOTHERAPY WITH INTERLEUKIN-2 IN RELATION TO THE PRETREATMENT LEVELS OF TUMOR-GROWTH FACTOR INSULIN-LIKE GROWTH-FACTOR-I
Authors: LISSONI P BARNI S ARDIZZOIA A FRIGERIO F PAOLOROSSI F CAZZANIGA M TANCINI G ROCCO F AAPRO M
Citation: P. Lissoni et al., CLINICAL EFFICACY OF CANCER SUBCUTANEOUS IMMUNOTHERAPY WITH INTERLEUKIN-2 IN RELATION TO THE PRETREATMENT LEVELS OF TUMOR-GROWTH FACTOR INSULIN-LIKE GROWTH-FACTOR-I, Tumori, 81(4), 1995, pp. 261-264
2ND-LINE THERAPY WITH INTERFERON-ALPHA PLUS VINBLASTINE IN METASTATICRENAL-CELL CANCER-PATIENTS PROGRESSED UNDER INTERLEUKIN-2 SUBCUTANEOUS IMMUNOTHERAPY
Authors: PAOLOROSSI F VILLA S BARNI S TANCINI G ANDRES M LISSONI P
Citation: F. Paolorossi et al., 2ND-LINE THERAPY WITH INTERFERON-ALPHA PLUS VINBLASTINE IN METASTATICRENAL-CELL CANCER-PATIENTS PROGRESSED UNDER INTERLEUKIN-2 SUBCUTANEOUS IMMUNOTHERAPY, Tumori, 81(1), 1995, pp. 45-47
PREDICTION OF RECURRENCE IN OPERABLE BREAST-CANCER BY POSTOPERATIVE CHANGES IN PROLACTIN SECRETION
Authors: LISSONI P BARNI S CAZZANIGA M ARDIZZOIA A ROVELLI F TANCINI G BRIVIO F FRIGERIO F
Citation: P. Lissoni et al., PREDICTION OF RECURRENCE IN OPERABLE BREAST-CANCER BY POSTOPERATIVE CHANGES IN PROLACTIN SECRETION, Oncology, 52(6), 1995, pp. 439-442
A BIOLOGICAL STUDY ON THE EFFICACY OF LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN IN THE TREATMENT OF CANCER-RELATED THROMBOCYTOPENIA
Authors: LISSONI P BARNI S BRIVIO F ROSSINI F FUMAGALLI L ARDIZZOIA A TANCINI G
Citation: P. Lissoni et al., A BIOLOGICAL STUDY ON THE EFFICACY OF LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN IN THE TREATMENT OF CANCER-RELATED THROMBOCYTOPENIA, Oncology, 52(5), 1995, pp. 360-362
A RANDOMIZED STUDY OF LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN VERSUS SUPPORTIVE CARE ALONE IN METASTATIC COLORECTAL-CANCER PATIENTS PROGRESSING UNDER 5-FLUOROURACIL AND FOLATES
Authors: BARNI S LISSONI P CAZZANIGA M ARDIZZOIA A MEREGALLI S FOSSATI V FUMAGALLI L BRIVIO F TANCINI G
Citation: S. Barni et al., A RANDOMIZED STUDY OF LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN VERSUS SUPPORTIVE CARE ALONE IN METASTATIC COLORECTAL-CANCER PATIENTS PROGRESSING UNDER 5-FLUOROURACIL AND FOLATES, Oncology, 52(3), 1995, pp. 243-245
IMMUNOENDOCRINE THERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUSMELATONIN OF LOCALLY ADVANCED OR METASTATIC ENDOCRINE TUMORS
Authors: LISSONI P BARNI S TANCINI G MAININI E PIGLIA F MAESTRONI GJM LEWINSKI A
Citation: P. Lissoni et al., IMMUNOENDOCRINE THERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUSMELATONIN OF LOCALLY ADVANCED OR METASTATIC ENDOCRINE TUMORS, Oncology, 52(2), 1995, pp. 163-166
MODULATION OF CANCER ENDOCRINE THERAPY BY MELATONIN - A PHASE-II STUDY OF TAMOXIFEN PLUS MELATONIN IN METASTATIC BREAST-CANCER PATIENTS PROGRESSING UNDER TAMOXIFEN ALONE
Authors: LISSONI P BARNI S MEREGALLI S FOSSATI V CAZZANIGA M ESPOSTI D TANCINI G
Citation: P. Lissoni et al., MODULATION OF CANCER ENDOCRINE THERAPY BY MELATONIN - A PHASE-II STUDY OF TAMOXIFEN PLUS MELATONIN IN METASTATIC BREAST-CANCER PATIENTS PROGRESSING UNDER TAMOXIFEN ALONE, British Journal of Cancer, 71(4), 1995, pp. 854-856
A CLINICAL-STUDY OF IMMUNOTHERAPY VERSUS ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE TREATMENT OF ADVANCED PANCREATIC ADENOCARCINOMA
Authors: LISSONI P ARDIZZOIA A MEREGALLI S BARNI S FOSSATI V BRIVIO F TANCINI G
Citation: P. Lissoni et al., A CLINICAL-STUDY OF IMMUNOTHERAPY VERSUS ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE TREATMENT OF ADVANCED PANCREATIC ADENOCARCINOMA, Oncology Reports, 1(6), 1994, pp. 1277-1280
LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS IMMUNOTHERAPY IN ASSOCIATION WITHTHE PINEAL HORMONE MELATONIN AS A FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR-CARCINOMA
Authors: ALDEGHI R LISSONI P BARNI S ARDIZZOIA A TANCINI G PIPERNO A POZZI M RICCI G CONTI A MAESTRONI GJM
Citation: R. Aldeghi et al., LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS IMMUNOTHERAPY IN ASSOCIATION WITHTHE PINEAL HORMONE MELATONIN AS A FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR-CARCINOMA, European journal of cancer, 30A(2), 1994, pp. 167-170
ROLE OF THE PINEAL-GLAND IN THE CONTROL OF MACROPHAGE FUNCTIONS AND ITS POSSIBLE IMPLICATION IN CANCER - A STUDY OF INTERACTIONS BETWEEN TUMOR-NECROSIS-FACTOR-ALPHA AND THE PINEAL HORMONE MELATONIN
Authors: LISSONI P BARNI S TANCINI G BRIVIO F TISI E ZUBELEWICZ B BRACZKOWSKI R
Citation: P. Lissoni et al., ROLE OF THE PINEAL-GLAND IN THE CONTROL OF MACROPHAGE FUNCTIONS AND ITS POSSIBLE IMPLICATION IN CANCER - A STUDY OF INTERACTIONS BETWEEN TUMOR-NECROSIS-FACTOR-ALPHA AND THE PINEAL HORMONE MELATONIN, Journal of biological regulators and homeostatic agents, 8(4), 1994, pp. 126-129
PRELIMINARY-STUDY ON MODULATION OF THE BIOLOGICAL EFFECTS OF TUMOR-NECROSIS-FACTOR-ALPHA IN ADVANCED CANCER-PATIENTS BY THE PINEAL HORMONE MELATONIN
Authors: BRACKOWSKI R ZUBELEWICZ B ROMANOWSKI W LISSONI P BARNI S TANCINI G MAESTRONI GJM
Citation: R. Brackowski et al., PRELIMINARY-STUDY ON MODULATION OF THE BIOLOGICAL EFFECTS OF TUMOR-NECROSIS-FACTOR-ALPHA IN ADVANCED CANCER-PATIENTS BY THE PINEAL HORMONE MELATONIN, Journal of biological regulators and homeostatic agents, 8(3), 1994, pp. 77-80
WEEKLY EPIRUBICIN PLUS LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS THERAPY INBREAST-CANCER - PRELIMINARY IMMUNOBIOLOGICAL RESULTS
Authors: LISSONI P BARNI S ARDIZZOIA A FOSSATI V PAOLOROSSI F TANCINI G
Citation: P. Lissoni et al., WEEKLY EPIRUBICIN PLUS LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS THERAPY INBREAST-CANCER - PRELIMINARY IMMUNOBIOLOGICAL RESULTS, Journal of biological regulators and homeostatic agents, 8(2), 1994, pp. 53-55
WEEKLY EPIRUBICIN PLUS LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS THERAPY INBREAST-CANCER - PRELIMINARY IMMUNOBIOLOGICAL RESULTS
Authors: LISSONI P BARNI S ARDIZZOIA A FOSSATI V PAOLOROSSI F TANCINI G
Citation: P. Lissoni et al., WEEKLY EPIRUBICIN PLUS LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS THERAPY INBREAST-CANCER - PRELIMINARY IMMUNOBIOLOGICAL RESULTS, Journal of biological regulators and homeostatic agents, 8(2), 1994, pp. 53-55
NORMALIZATION OF IDIOPATHIC ARTERIAL-HYPERTENSION FOLLOWING CANCER-IMMUNOTHERAPY WITH INTERLEUKIN-2
Authors: LISSONI P BASTONE A BARNI S TANCINI G GALLI MA
Citation: P. Lissoni et al., NORMALIZATION OF IDIOPATHIC ARTERIAL-HYPERTENSION FOLLOWING CANCER-IMMUNOTHERAPY WITH INTERLEUKIN-2, Journal of biological regulators and homeostatic agents, 8(2), 1994, pp. 65-66
Risultati: 1-25 | 26-50 | 51-75 | 76-77